QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
Log in
NASDAQ:KMDA

Kamada Stock Forecast, Price & News

$6.62
-0.06 (-0.90 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$6.59
Now: $6.62
$6.78
50-Day Range
$6.39
MA: $7.46
$8.46
52-Week Range
$4.40
Now: $6.62
$13.33
Volume149,242 shs
Average Volume223,593 shs
Market Capitalization$294.72 million
P/E Ratio14.09
Dividend YieldN/A
Beta1.28
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus, as well as human transferrin that is used as a cultural medium for diagnostic assays and cell cultures. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. The company's products in pipeline are G1-AAT (IV) for graft versus host disease and L1-AAT (1V) for lung transparent that are in Phase II stage; and Inhaled AAT for AAT deficiency, which is in Phase II and III stages. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion Biopharma. The company was founded in 1990 and is headquartered in Rehovot, Israel.
Read More
Kamada logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KMDA
CUSIPN/A
Phone972-8940-6472
Employees429

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$127.19 million
Cash Flow$0.54 per share
Book Value$3.04 per share

Profitability

Net Income$22.25 million

Miscellaneous

Market Cap$294.72 million
Next Earnings Date2/10/2021 (Estimated)
OptionableNot Optionable
$6.62
-0.06 (-0.90 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kamada (NASDAQ:KMDA) Frequently Asked Questions

How has Kamada's stock been impacted by COVID-19 (Coronavirus)?

Kamada's stock was trading at $5.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, KMDA shares have increased by 28.5% and is now trading at $6.62.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Kamada?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kamada
.

What stocks does MarketBeat like better than Kamada?

Wall Street analysts have given Kamada a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kamada wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Kamada's next earnings date?

Kamada is scheduled to release its next quarterly earnings announcement on Wednesday, February 10th 2021.
View our earnings forecast for Kamada
.

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) posted its earnings results on Wednesday, November, 11th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. Kamada had a return on equity of 13.22% and a net margin of 15.10%.
View Kamada's earnings history
.

What guidance has Kamada issued on next quarter's earnings?

Kamada issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, November, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $132-137 million, compared to the consensus revenue estimate of $134.75 million.

What price target have analysts set for KMDA?

2 analysts have issued 1-year price targets for Kamada's stock. Their forecasts range from $11.00 to $11.00. On average, they expect Kamada's stock price to reach $11.00 in the next year. This suggests a possible upside of 66.2% from the stock's current price.
View analysts' price targets for Kamada
.

Are investors shorting Kamada?

Kamada saw a increase in short interest in the month of October. As of October 30th, there was short interest totaling 465,700 shares, an increase of 26.2% from the October 15th total of 368,900 shares. Based on an average trading volume of 473,100 shares, the short-interest ratio is presently 1.0 days. Currently, 1.9% of the shares of the company are sold short.
View Kamada's Short Interest
.

Who are some of Kamada's key competitors?

What other stocks do shareholders of Kamada own?

Who are Kamada's key executives?

Kamada's management team includes the following people:
  • Mr. Amir London, Chief Exec. Officer (Age 51, Pay $546.97k)
  • Mr. Chaime Orlev, Chief Financial Officer (Age 50, Pay $294.55k)
  • Mr. Eran Nir, VP of Operations (Age 47, Pay $276.02k)
  • Yifat Philip Esq., VP of Legal, Gen. Counsel & Corp. Sec.
  • Ms. Hanni Neheman, VP of Marketing & Sales (Age 50)
  • Ms. Ariella Raban, VP of HR (Age 44)

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

Who are Kamada's major shareholders?

Kamada's stock is owned by many different institutional and retail investors. Top institutional investors include Phoenix Holdings Ltd. (2.07%), Acadian Asset Management LLC (1.69%), Altshuler Shaham Ltd (1.23%), Morgan Stanley (0.86%), Diametric Capital LP (0.26%) and ARK Investment Management LLC (0.21%).

Which major investors are selling Kamada stock?

KMDA stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Phoenix Holdings Ltd., AJO LP, Seizert Capital Partners LLC, and BlackRock Inc..

Which major investors are buying Kamada stock?

KMDA stock was acquired by a variety of institutional investors in the last quarter, including Altshuler Shaham Ltd, Diametric Capital LP, ARK Investment Management LLC, Morgan Stanley, Jane Street Group LLC, O Shaughnessy Asset Management LLC, and Ritholtz Wealth Management.

How do I buy shares of Kamada?

Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $6.62.

How big of a company is Kamada?

Kamada has a market capitalization of $294.72 million and generates $127.19 million in revenue each year. The biotechnology company earns $22.25 million in net income (profit) each year or $0.55 on an earnings per share basis. Kamada employs 429 workers across the globe.

What is Kamada's official website?

The official website for Kamada is www.kamada.com.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.